BiotechTube

SPYK04

Phase 1Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Locally Advanced or Metastatic Solid Tumors

Conditions

Locally Advanced or Metastatic Solid Tumors

Trial Timeline

Sep 10, 2020 → Sep 30, 2026

NCT ID
NCT04511845

About SPYK04

SPYK04 is a phase 1 stage product being developed by Chugai Pharmaceutical for Locally Advanced or Metastatic Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT04511845. Target conditions include Locally Advanced or Metastatic Solid Tumors.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04511845Phase 1Active

Competing Products

20 competing products in Locally Advanced or Metastatic Solid Tumors

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
Tadalafil + GemcitabineEli LillyPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + RilvegostomigDaiichi SankyoPhase 1
33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
41
zolbetuximabAstellas PharmaPre-clinical
23
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
enfortumab vedotin (EV)Astellas PharmaPre-clinical
23
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
ASP3082Astellas PharmaPhase 2
52
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
ASP1948Astellas PharmaPhase 1
33
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )Sun PharmaceuticalPhase 2
52
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
41

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77